Abstract:Objective To evaluate the clinical results of treatment for osteosarcoma of the extremities with adjuvant chemotherapy regimen Methods Sixty seven patients with ⅡB extremity osteosarcoma were treated with the combination of adjuvant chemotherapy regimen and definitive surgery Forty seven of them were male and twenty four were female The mean age of the patients at the time of diagnosis was 20 years (ranged 10～51 years) Sixty four lesions involved the lower extremity, with 45 involving the distal femur, 14 the upper tibia, 3 the upper fibula and 2 the proximal femur; Three involved the upper end of the humerus The study of subtype of osteosarcoma revealed that 51 were osteoblastic, 6 chondroblastic, 5 fibroblastic and 5 the other subtypes The patients were divided into three groups according to the adjuvant chemotherapy regimen given, the first group consisted of 23 cases, who were treated with the combination of the presurgical cisplatin hyperthermic isolated limb perfusion (CDP-HILP) and postoperative chemotherapy; the second group of 20 cases, who were treated with the combination of the presurgical CBP-HILP and postoperative chemotherapy; and the other 24 cases were treated with postoperative chemotherapy alone Twenty nine of the 67 patients treated surgically had limb salvage procedures; 35 had amputations and 3 had Tikhoff-Limbergs surgery Multiple histologic sections were procured and examined from each of the surgical specimens in the patients who were treated with preoperative HILP to determine the effect of chemotherapy All patients were followed from 3 to 9 years, and the data were statistically analeyed using SPSS 7 0 Results Among 67 cases, 41 (61 19%) had relapse free survival(RFS) in 2 years after surgery, 37 (55 22%) had RFS in 3 years after surgery, and RFS probability at 5 years after surgery was 49 56% Log-rank analysis showed no significant difference in RFS probability among the three groups(P=0 517 1), but there was a significant difference in RFS probability between patients who had limb salvage procedure and those had amputation(P=0 009 7) Age, sex, site and subtype were not significant prognostic variables in this group of patients Correction analysis revealed that the RFS probability were not related with the rate of the tumor necrosis (P=0 058) Conclusion The data revealed that 1) The chemotherapy regimen mainly including platinic drugs was effective treatment for osteosarcoma ,and was more simple and less expensive than any previous reported chemotherapy for steosarcoma, 2) CDP of chemotherapy regimen for osteosarcoma, which had more nephritic and audio toxicity could be replaced by CBP , And 3)Whether the preoperative chemotherapy is suitable for the patients in whom amputation is inevitable (based on age ,size, and involvement of local structure) remains unclear

Perioperative Rh-Endostatin with Chemotherapy Improves the Survival of Conventional Osteosarcoma Patients: a Prospective Non-Randomized Controlled Study

The Preliminary Report of a Randomized Controlled Multicenter Study of First-Line Chemotherapy Regimen Combined with Angiogenesis Inhibitor for Osteosarcoma of the Extremities

A Clinical Observation of Rh-Endostatin (endostar) Combined with Chemotherapy for Osteosarcoma

Antitumor Effects of Combining Doxorubicin Hydrochloride with Recombinant Human Endostatin in an Osteosarcoma Model

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas

Endostar ( rh‐endostatin ) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

Chemotherapy on vascular normalization in patients of advanced non-small cell lung cancer

Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data

The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study

Efficacy and safety of recombinant human endostatin combined with whole-brain radiotherapy in patients with brain metastases from NSCLC.

Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer

Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways

Efficacy and Safety of Endostar in the Treatment of Advanced Lung Squamous Cell Carcinoma.

Influence of Different Drug Delivery Methods for Endostar Combined with a Gemcitabine/cisplatin Regimen in Locally Advanced or Metastatic Lung Squamous Cell Carcinoma

Continuous Intravenous Infusion of Recombinant Human Endostatin Combined with Concurrent Etoposide Plus Cisplatin and Radiotherapy for Treatment of Unresectable Stage Iii Non-Small-Cell Lung Cancer (helper): A Phase 2, Multicentre Study